Processing math: 100%
论著
ENGLISH ABSTRACT
住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建
赵鹏
陈静
杨光红
彭燕清
作者及单位信息
·
DOI: 10.3760/cma.j.cn112147-20210705-00467
Nomogram model for predicting risk of anti-tuberculosis drug-induced liver injury among inpatients with tuberculosis
Zhao Peng
Chen Jing
Yang Guanghong
Peng Yanqing
Authors Info & Affiliations
Zhao Peng
School of Public Health, Guizhou Medical University, Guiyang 550025, China
Chen Jing
School of Public Health, Guizhou Medical University, Guiyang 550025, China
Yang Guanghong
School of Public Health, Guizhou Medical University, Guiyang 550025, China
Peng Yanqing
Public Health Treatment Center of Guiyang City, Guiyang 550003, China
·
DOI: 10.3760/cma.j.cn112147-20210705-00467
1760
372
0
0
12
5
PDF下载
APP内阅读
摘要

目的探讨住院结核患者发生抗结核药物性肝损伤(ATB-DILI)的影响因素,并建立Nomogram风险预测模型。

方法回顾性收集2017年1月至2021年6月贵阳市公共卫生救治中心收治的5 681例住院结核病患者作为研究对象,其中男3 342例,女2 339例,将住院治疗过程中发生ATB-DILI的患者作为病例组(214例),非ATB-DILI患者作为对照组(5 427例)。回顾性分析患者的基线特征、结核病情、行为及疾病相关资料等,经卡方检验和多因素logistic 回归筛选分析影响因素,据此构建Nomogram模型并进行验证。使用决策曲线评估模型的临床实际应用价值。

结果本次研究中共有3.8%(214/5 681)例患者发生ATB-DILI。经多因素logistic 回归分析得出肺外结核( OR=1.876, P<0.001)、营养不良( OR=4.411, P<0.001)、合并基础肝病( OR=4.961, P<0.001)以及间断使用护肝药( OR=2.137, P=0.007)是其发生ATB-DILI的独立危险因素;全程使用护肝药( OR=0.292, P<0.001)是其保护因素。将以上5个相关影响因素构建Nomogram模型,ROC曲线下面积为0.749(95% CI:0.713~0.786),敏感度0.640,特异度0.752。使用Bootstrap法内部重复抽样1 000次进行验证,平均绝对误差0.003,校正曲线和理想曲线基本拟合,预测值和实际值一致性较好。Hosmer-lemeshow检验显示,模型具有较好拟合度( χ2 =3.068, P=0.381)。决策曲线显示Nomogram模型在高风险阈值范围(0.10~0.68)时,有着一定的临床实用性。

结论本次研究所构建的住院结核患者抗结核药物性肝损伤Nomogram风险预测模型具有较好的预测性、一致性和临床实用性,能为临床在抗结核治疗过程中防控ATB-DILI并制定个体化治疗方案提供依据。

结核病;药物性肝损伤;抗结核药;影响因素;Nomogram风险预测模型
ABSTRACT

ObjectiveTo explore the influencing factors of anti-tuberculosis drug-induced liver injury (ATB-DILI) in hospitalized tuberculosis patients, and to establish a risk prediction model of Nomogram.

MethodsA retrospective study was conducted on 5 681 tuberculosis patients admitted to Guiyang public health treatment center from January 2017 to June 2021, including 3 342 males and 2 339 females. The inpatients with ATB-DILI were selected as the case group (214 cases) and the non-ATB-DILI patients as the control group (5 427 cases). The baseline characteristics, tuberculosis condition, behavior and disease-related data of the patients were retrospectively analyzed, and the influencing factors were screened by chi-square test and multivariate logistic regression, based on which the Nomogram model was constructed and verified. The decision curve was used to evaluate the clinical application value of the model.

ResultsIn this study, 3.8%(214/5 681) patients developed ATB-DILI. Multivariate logistic regression analysis showed that extrapulmonary tuberculosis ( OR=1.876, P<0.001), malnutrition ( OR=4.411, P<0.001), complicated with underlying liver disease ( OR=4.961, P<0.001) and intermittent use of hepatoprotective drugs ( OR=2.137 , P=0.007) were independent risk factors for ATB-DILI, while whole-course use of hepatoprotective drugs ( OR=0.292, P<0.001) was protective factor. The Nomogram model was constructed based on the above five related factors. The area under the receiver operating characteristic (ROC) curve was 0.749 (95% CI:0.713-0.786), the sensitivity was 0.640, and the specificity was 0.752, respectively. The Bootstrap method was used for internal repeated sampling for 1 000 times, the average absolute error was 0.003, the correction curve and the ideal curve were basically fitted, and the predicted values were in good agreement with the actual values. Hosmer-lemeshow test showed that the model had a good degree of fit ( χ2 =3.068, P=0.381). The decision curve showed that the Nomogram model had certain clinical practicability in the high risk threshold range (0.10-0.68).

ConclusionsThe Nomogram model for risk predicting ATB-DILI among inpatients with tuberculosis in this study has good predictability, consistency and clinical practicability, and can provide a basis for clinical prevention and control of ATB-DILI and individualized treatment in the process of anti-tuberculosis treatment.

Tuberculosis;Drug-induced liver injury;Antitubercular agents;Influencing factors;Nomogram predictive model
Chen Jing, Email: nc.defanabiskfgnijnehc
引用本文

赵鹏,陈静,杨光红,等. 住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建[J]. 中华结核和呼吸杂志,2022,45(02):171-176.

DOI:10.3760/cma.j.cn112147-20210705-00467

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
结核病是由结核分枝杆菌所引起的一种严重慢性呼吸道传染性疾病,位列全球十大死因之一,是全球性的公共卫生问题。2019年,全球范围估计约有996万结核病新发病例,而中国病例数约占8.4%,报告的发病率为58/10万,结核病新发患者83.3万,是世界上结核病高负担的30个国家之一 1。据贵州省法定传染病报告系统显示,结核病发病率居28种传染病之首,近3年的发病率依次为123/10万、114/10万、102/10万,每年新发病例数4万左右。
结核病化疗用药原则是“早期、规律、全程、适量、联合”。主要涉及的药物有异烟肼(Isniazid,INH)、利福平(Rifampicin,RFP)、吡嗪酰胺(Pyrazinamide,PZA)、丙硫异烟胺(Protionamide,PTH)、对氨基水杨酸(Paza-aminosalicylate,PAS)等,而这些药物在长期使用过程中会产生各种不良反应,其中以药物性肝损伤(drug-induced liver injury,DILI)危害最大 2。抗结核药物性肝损伤(anti-tuberculosis drug-induced liver injury,ATB-DILI)是指在抗结核药物的使用期间,药物及其代谢产物引起肝细胞损伤或对肝脏产生超敏反应所致的病理过程 3。我国一项多中心大样本回顾性研究显示,确诊为DILI的25 927例患者中,抗结核药物所致肝损伤居第2位,占21.99% 4。抗结核治疗过程中发生DILI时,可能会诱发耐药结核病的产生,导致结核病中断治疗和治疗失败;甚至导致肝功能衰竭,危及患者生命 5
Nomogram建立在多因素回归分析基础上,将多个预测指标进行整合,预测结局发生风险,使复杂的方程转化为可视化图形。Nomogram可较为准确地预测某些疾病在未来的发生率及复发率 6。以往研究多是侧重ATB-DILI的危险因素分析,较少纳入模型对ATB-DILI进行预测。鉴于此,本项研究旨在通过回顾性调查建立Nomogram模型,预测住院结核患者抗结核治疗过程中发生ATB-DILI的风险,为临床防控ATB-DILI以及制定有效个体化治疗方案提供参考。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
World Health Organization. Global tuberculosis report 2020[R]. Geneva:WHO, 2020.
返回引文位置Google Scholar
百度学术
万方数据
[2]
Zhao H , Wang Y , Zhang T ,et al. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study[J]. Med Sci Monit, 2020,26:e920350. DOI: 10.12659/MSM.920350 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019,42(5):343-356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Shen T , Liu Y , Shang J ,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019,156(8):2230-2241.e11. DOI: 10.1053/j.gastro.2019.02.002 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Song JH , Yoon SY , Park TY ,et al. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study[J]. Respir Res, 2019,20(1):283. DOI: 10.1186/s12931-019-1256-y .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Lin C , Sun XS , Liu SL ,et al. Establishment and validation of a nomogram for nasopharyngeal carcinoma patients concerning the prognostic effect of parotid lymph node metastases[J]. Cancer Res Treat, 2020,52(3):855-866. DOI: 10.4143/crt.2019.772 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
中华人民共和国国家卫生和计划生育委员会, 肺结核诊断(WS+288-2017)[S]. 中华人民共和国卫生行业标准, 2017.
[8]
Leung CC , Li T , Lam TH ,et al. Smoking and tuberculosis among the elderly in Hong Kong[J]. Am J Respir Crit Care Med, 2004,170(9):1027-1033. DOI: 10.1164/rccm.200404-512OC .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Tostmann A , Boeree MJ , Aarnoutse RE ,et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review[J]. J Gastroenterol Hepatol, 2008,23(2):192-202. DOI: 10.1111/j.1440-1746.2007.05207.x .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Sun Q , Zhang Q , Gu J ,et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study[J]. Pharmacoepidemiol Drug Saf, 2016,25(8):908-917. DOI: 10.1002/pds.3988 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
吴玉华,武谦虎. 抗结核药致肝损害1949例文献分析[J]. 西北药学杂志, 2015, (6):750-753. DOI: 10.3969/j.issn.1004-2407.2015.06.028 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Horák P , Horová B , Koutníková H ,et al. Splenic abscess as a rare symptom of the extrapulmonary tuberculosis-case report[J]. Rozhl Chir, 2019,98(7):297-300.
返回引文位置Google Scholar
百度学术
万方数据
[13]
杨松,王乐乐,李同心,. 肺外结核流行病学研究进展[J]. 中华流行病学杂志, 2021,42(1):171-176. DOI: 10.3760/cma.j.cn112338-20200814-01067 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
谭守勇,覃红娟,黎燕琼. 营养不良是抗结核药物性肝功能损伤的危险因素[J]. 中国防痨杂志, 2014,36(1):64-66. DOI: 10.3969/j.issn.1000-6621.2014.01.014 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Naidoo S , Evans D , Jong E ,et al. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury[J]. S Afr Med J, 2015,105(5):393-396. DOI: 10.7196/samj.8217 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Ali N , Gupta N , Saravu K . Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India[J]. Drug Discov Ther, 2020,14(3):135-138. DOI: 10.5582/ddt.2020.03029 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Zheng J , Guo MH , Peng HW ,et al. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies[J]. Epidemiol Infect, 2020,148:e290. DOI: 10.1017/S0950268820002861 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Mo X , Xu X , Ren Z ,et al. Patients with tuberculous meningitis and hepatitis B co-infection have increased risk for antituberculosis drug-induced liver injury and poor outcomes[J]. Infect Dis (Lond), 2020,52(11):793-800. DOI: 10.1080/23744235.2020.1788223 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Chang TE , Huang YS , Chang CH ,et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis[J]. J Chin Med Assoc, 2018,81(2):111-118. DOI: 10.1016/j.jcma.2017.10.002 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
沈弢,段昭君,庄辉. 药物性肝损伤的流行病学[J]. 肝脏, 2015, (10):819-823. DOI: 10.3969/j.issn.1008-1704.2015.10.020 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
冯地忠,官正喜,蒋锋,. 预防性保肝对居家治疗结核患者肝损伤的疗效观察[J]. 解放军预防医学杂志, 2020,38(3):52-54.
返回引文位置Google Scholar
百度学术
万方数据
[22]
Ding R , Zhou X , Huang D ,et al. Nomogram for predicting advanced liver fibrosis and cirrhosis in patients with chronic liver disease[J]. BMC Gastroenterol, 2021,21(1):190. DOI: 10.1186/s12876-021-01774-w .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
陈静,Email: nc.defanabiskfgnijnehc
B

赵鹏:实施研究、采集数据、分析数据;撰写文章、统计学分析;陈静:设计试验、审阅文章、获取研究经费;杨光红:审阅文章、支持性贡献

C

赵鹏, 陈静, 杨光红等. 住院结核患者抗结核药物性肝损伤的Nomogram风险预测模型构建[J]. 中华结核和呼吸杂志, 2022, 45(2): 171-176. DOI: 10.3760/cma.j.cn112147-20210705-00467.

D
所有作者声明无利益冲突
E
贵阳市科技计划项目 (筑科合同[2018]1-47号)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号